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Abstract
The ADAMs are transmembrane proteins implicated in proteolysis and cell adhesion.
Forty gene members of the family have been identified, of which 21 are believed to
be functional in humans. As proteases, their main substrates are the ectodomains of
other transmembrane proteins. These substrates include precursor forms of growth
factors, cytokines, growth factor receptors, cytokine receptors and several different
types of adhesion molecules. Although altered expression of specific ADAMs has
been implicated in different diseases, their best-documented role is in cancer
formation and progression. ADAMs shown to play a role in cancer include ADAM9,
ADAM10, ADAM12, ADAM15 and ADAM17. Two of the ADAMs, i.e., ADAM10 and 17
appear to promote cancer progression by releasing HER/EGFR ligands. The released
ligands activate HER/EGFR signalling that culminates in increased cell proliferation,
migration and survival. Consistent with a causative role in cancer, several ADAMs are
emerging as potential cancer biomarkers for aiding cancer diagnosis and predicting
patient outcome. Furthermore, a number of selective ADAM inhibitors, especially
against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least
one of these inhibitors is now undergoing clinical trials in patients with breast
cancer.
Review
The ADAMs are a family of multidomain proteins shown to be involved in both
proteolysis and cell adhesion [for review, see refs [1-3]]. Although primarily located on
the cell membrane, soluble forms have been described for some ADAMs. The best
established role for ADAMs is the activation of the proforms of certain growth factors
and cytokines as well as the shedding of the extracellular domains of growth factor
receptors and adhesion proteins. ADAMs thus play a role in remodelling or processing
of cell membrane proteins. Several of the substrates processed by ADAMs, especially
by ADAM10 and ADAM17, have been implicated in the pathogenesis or progression
of cancer [for reviews, see refs [4,5]], though some proteolytically inactive ADAMs
may also play important roles in carcinogenesis (summarised in Table 1). The aim of
this article is to review the role of ADAMs in malignancy, focusing especially on their
potential use as cancer biomarkers and therapeutic targets. Firstly however, we briefly
review the protein structure and biological activities of ADAMs.
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Structure of ADAM Proteins
The generalised structure of an ADAM protein contains 8 distinct domains or regions.
In the typical ADAM protein, these domains are a signal domain, a prodomain, a
metalloproteinase domain, a disintegrin or integrin-binding domain, a cysteine rich
region, an EGF (epidermal growth factor)-like domain, a transmembrane sequence and
an intracellular C-terminal end [1]. Like most proteases, the ADAMs are initially
synthesised as enzymatically-inactive precursor proteins. As with MMPs, this inactive
state in most of the ADAMs is due to the interaction of a cysteine residue in the pro-
domain with the zinc ion at the catalytic site. For protease activation, this prodomain
is removed by a furin-like convertase or by autocatalysis, depending on the specific
ADAM [1,2]. This cysteine switch mechanism however, does not appear to play a role
in maintaining the zymogen state of ADAM17 [6].
Next to the prodomain is the MMP-like domain. Although all ADAMs possess this
sequence, only about 50% exhibit protease activity. Thus, of the 21 human ADAMs
identified, only 13 are proteolytically active. ADAMs shown to exhibit protease activity
include ADAM9, 10, 12, 15, 17, 19, 28 and 33. Currently, protease activity is the best-
defined function of ADAMs, with most of the putative substrates currently identified
being transmembrane proteins.
Downstream of the MMP domain is the disintegrin domain. This sequence, which is
found in all ADAMs binds to integrins, a group of adhesion proteins involved in cell













ADAM8 Shedding of adhesion molecules, leukocyte receptors, neutrophil infiltration, osteoclast
stimulation
ADAM9 a-secretase activity, cellular adhesion
ADAM10 a-secretase activity, shedding of TNF a, EGF, betacellulin, HER2, Notch, and collagen IV,
cellular adhesion
ADAM12 Cellular adhesion, shedding of HB-EGF
ADAM15 Cellular adhesion
ADAM17 Release of several growth factor ligands, e.g., TNF-alpha and specific EGFR/HER ligands,
cellular adhesion
ADAM19 Unknown
ADAM28 Shedding of IGFBP3
ADAM33 Involved in pathogenesis of gastric cancer via IL-18 secretion
*These functions have been reviewed in detail in refs [1-5].
LPL; lipoprotein lipase, CLL; chronic lymphocytic leukemia, TNFa; tumour necrosis factor-alpha, EGF; epidermal growth
factor, HB-EGF; heparin -binding-EGF, IGFBP3; insulin-like growth factor-binding protein 3, IL-18; interleukin-18
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adhesion, migration and cell signalling [7]. It should be stated that most of the work
relating to the binding of disintegrins to integrins has been carried out in vitro using
recombinant disintegrin domains [8]. The biological relevance of these findings are
thus unclear.
The function(s) of the remaining domains, i.e., the cysteine-rich region, EGF-like
sequence and cytoplasmic remain to be determined. In some of the ADAMs however,
the cysteine region has been implicated in regulating protease activity and controlling
substrate specificity [9]. The C-terminal domain of ADAM17 has been shown to
undergo phosphorylation at different sites including Thr735 and Ser819 [10-14]. Thus,
phosphorylation at Thr735 was found to be necessary for ADAM17-catalysed shedding
of TGF-alpha [12]. With ADAM15, phosphorylation of the cytoplasmic domain
resulted in interaction with several potential signalling proteins, including the Src
kinases, Hck and Lek [14]. It was unclear whether or not this interaction led to altered
intracellular cell signalling.
Role of ADAMs in Cancer Formation and Progression
Evidence that ADAMs play a causal role in cancer
Studies from cell lines grown in culture, animal models and human malignancies sug-
gest that a number of ADAMs are involved in cancer formation and/or progression
[4,5]. Specific ADAMs implicated in these processes include ADAM9, ADAM10,
ADAM12, ADAM15 and ADAM17. Of these different ADAMs, the strongest evidence
for a role in malignancy exists for ADAM17, which is also known as TACE (tumour
necrosis factor alpha converting enzyme). Briefly, the evidence implicating ADAMs in
malignancy is as follows [4,5]:
● Inhibition of ADAM17 activity or downregulation of its expression decreased
growth of breast cancer cells in vitro and reversed their morphological appearance
to that approximating normal cells [15].
● Several studies have shown that increased expression of certain ADAMs
enhanced in vitro invasion, proliferation and promoted tumour formation in vivo
[16-21], while decreased expression reduced these processes.
● Deficiency of specific ADAMs such as ADAM9, 15 and 17 resulted in decreased
growth of heterotopically injected tumour cells in mice models [22,23].
● Correlations exist between between levels of specific ADAMs and parameters of
tumour progresion (eg., tumour size, grade, metastasis to local lymph nodes and
patient outcome) in human cancers [26-31] and
● Selective inhibitors against certain ADAMs reduce or block tumour cell growth
in model system [32-34].
Mechanisms by which ADAMs play a role in cancer
Activation of positively-stimulating pathways
ADAMs could potentially promote cancer formation and progression using several dif-
ferent mechanisms. One of the most likely of these involves the release or activation of
positively-stimulating growth factors (Figure 1). Many of these growth factors are initi-
ally synthesised as inactive transmembrane precursor proteins that require conversion
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to an active state in order to exert maximun activity. Amongst the best-studied
growth-stimulating factors that are activated by ADAMs are the EGFR/HER family of
ligands. Conversion of these ligands to their active state is primarily mediated by either
ADAM10 or ADAM17. Thus, ADAM17 appears to be the physiological sheddase for
TGF-alpha, amphiregulin, HB-EGF, and epiregulin. ADAM10, on the other hand,
appears to be the major sheddase for the release of EGF and betacellulin [35,36]. In
certain situations however, other ADAMs including ADAM8, 9, 12, 17 and 19 can acti-
vate one or more of these ligands [37].
The shed form of these ligands binds to one or more of the EGFR/HER family of
receptors. Four members of this family exist, i.e., HER1 (c-erbB1), HER2 (c-erbB2),
HER3 (c-erbB3) and HER4 (c-erbB4). These 4 receptors have a similar general struc-
ture that includes an extracellular domain, a transmembrane domain and an intracellu-
lar domain [38-40]. All of these receptors, apart from HER2, can be directly activated
following ligand binding. Following homo- or heterodimerisation, downstream signal-
ling from these receptors activates several different pathways including the mitogen-
activated protein kinase (MAPK) pathway, the phosphatidylinositol 3-kinase (PI3K)
pathway and janus kinase/signal transducer and activator of transcriptional (JAK/
STAT) pathway. This signalling results in some of the classical hall markers of malig-
nancy such as enhanced cell proliferation, increased cell motility and increased cell
survival [38-40].
Substantial evidence implicating ADAM-mediated growth factor ligand release and
EGFR signalling in cancer cell proliferation or migration is now available. Singh et al
Figure 1 Mode of action of ADAMs in the activation of EGFR/HER receptor signalling. ADAMs
(primarily ADAM10 and ADAM17) are involved in proteolytic ectodomain shedding of membrane bound
ligands. The released ligands (for example, EGF, HB-EGF, TGFa, heregulins) are free to bind to and activate
EGFR, HER3 and HER4. Following receptor dimerisation (though HER3 has weak tyrosine kinase activity, its
preferred dimerization partner is HER2), downstream signalling through many pathways is activated,
including MAPK, PI3K and JAK/STAT.
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[41] showed that UV irradiation of skin cancer cells activated ADAM9 and 17 which
was followed by amphiregulin shedding, EGFR transactivation and increased cell prolif-
eration. In another study, Zheng et al [21] reported that ADAM17, via ligand release
and activation of the EGFR-PI3K-AKT pathway, enhanced in vitro breast cancer cell
proliferation and invasion. In a further study, Mendelson et al [42] showed that treat-
ing mouse embryonic fibroblasts with platelet derived growth factor receptor beta
(PDGFRb) led to activation of ADAM17, release of EGFR ligands and EGFR/ERK sig-
nalling. This cascade of events ultimately resulted in enhanced migration.
While shedding of the extracellular domain of the HER ligands results in receptor
binding, at least for heparin binding-epidermal growth factor [HB-EGF], it can also
lead to translocation of its C-terminal fragment from the cell membrane into the
nucleus and regulation of cell proliferation. This translocation of the C-terminal
domain of HB-EGF has been shown both in keratinocytes [43] and gastric cancer cells
[44] and is thus another possible mechanism by which ADAM-catalysed shedding of
growth factors can alter cell proliferation.
Inactivation of growth-inhibitory pathways
Inactivation of growth inhibitory signalling systems would be expected to produce the
same end result as activation of positively-activating growth factors. One of the best exam-
ples of a negatively-acting growth factor is TGFb which signals via TGFbR1 and TGFbR2
[45]. In normal and early malignant cells, TGFb inhibits proliferation. In contrast in pro-
gressive malignancy, TGFb promotes proliferation [45]. Recently, ADAM17 was reported
to mediate shedding of the type 1 TGFb receptor [46]. As a result, TGFb signalling was
decreased which in turn led to decreased growth inhibition. According to Liu et al [46],
this ADAM17 mediated reduction in growth inhibition complements the growth stimula-
tion, resulting from increased release of the EGFR/HER ligands, see above.
Shedding of adhesion proteins
ADAM-mediated shedding of adhesion proteins may also result in increased cell prolif-
eration. Maretzky et al [47] showed that ADAM10 caused shedding of the extracellular
domain of cadherin E, which resulted in the translocation of beta-catenin to the
nucleus and enhanced proliferation. In other work, Najy et al [48] found that an
ADAM15-mediated shed form of cadherin E bound to and activated HER2 in breast
cancer cells [48]. The shed form of cadherin E formed a complex with HER2 and
HER3, that gave rise to enhanced ERK signalling, which in turn, led to increased prolif-
eration and migration.
It was mentioned above that shedding of cadherin E resulted in increased cell prolif-
eration. As well as enhancing cell proliferation, this shedding might also be expected to
weaken cell:cell interaction and thus allow dissociation of potential invasive and meta-
static cells in the primary cancer. Such dissociation could potentially place a malignant
cell or group of cells on their pathway to metastais. Shedding of other adhesion proteins
such as L-selectin, ICAM-1 or VCAM, on the other hand, might be expected to modu-
late binding of tumour cells to the vasculature wall and thus play a role in the intravasa-
tion [i.e., exiting of tumour cells from the vasculature into a distant organ].
Potential involvement in mediating angiogenesis
Finally, ADAMs may promote cancer growth and metastasis by mediating angiogenesis
or pathological neovascularisation. Angiogenesis is defined as the protrusion and out-
growth of capillary buds and sprouts from pre-existing blood vessels [49]. This process
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is essential for tumours to grow beyond approximately 2 mm in diameter. Early evi-
dence implicating ADAMs in angiogenesis was the finding of pulmonary hypovascular-
isation in mice expressing catalytically inactive ADAM17 [50]. More recently, Gooz et
al [51] showed that knockdown of ADAM17 expression using siRNA decreased
endothelial cell proliferation and invasion in vitro. Furthermore, in a mouse model,
Weskamp et al [25] reported that deletion of ADAM17 resulted in pathological neo-
vascularisation and reduced growth of injected tumour cells. In this animal model,
neither developmental nor vascular homeostasis was affected by the loss of ADAM17.
Other ADAMs implicated in pathological neovascularisation include ADAM9 [22] and
ADAM15 [23,24].
ADAMs as Biomarkers in Cancer
Biomarkers are potentially useful in cancer detection (screening and aiding diganosis),
asssessing prognosis, upfront predicting likely response or resistance to therapy and
monitoring ongoing therapy [for review, see ref. 52]. In recent years, several prelimin-
ary reports suggested that a number of different ADAMs may act as cancer biomar-
kers. This evidence is briefly reviewed below.
ADAMs as diagnostic aids in cancer
For aiding cancer diagnosis, a biomarker should be specifically altered in the majority
of patients with a specific malignancy or premalignant condition. Furthermore, it
should be measurable in a readily available fluid such as serum or urine. In recent
years, a number of ADAMs have been detected in these fluids from patients with can-
cer. One of the first ADAMs shown to have diagnostic potential was ADAM12 in
breast cancer. Using Western blotting, Roy et al [53], reported that urinary levels of
ADAM12 were significantly increased in patients with breast cancer vis-à-vis a healthy
control group. Furthermore, the proportion of patients with high levels of this ADAM
was significantly greater in the breast cancer patients than in the healthy controls.
Levels were disease stage-related, progressively increasing from patients with in situ
disease, to those with locally invasive disease to those with metastatic disease. Using
logistic regression analysis, the authors calculated that the predictive probability of the
presence of breast cancer was ≥ 80%, when levels of ADAM12 exceeded 40 arbitrary
units [53].
In a follow-up study to above, Pories et al [54] found that urinary ADAM12 levels
were also increased in women with putative premalignant lesions of invasive breast
cancer such as atypical hyperplasia and lobular carcinoma in situ, compared to levels
in healthy controls. This finding, if confirmed, suggests that measurement of ADAM12
in urine could identify women at increase risk of developing breast cancer. Clearly,
these preliminary but promising findings, require confirmation in larger studies. It
should be stated that none of the available serum markers for breast cancer are
increased in patients with early disease and are thus of little value in identifying
women at increased risk of developing this malignancy [55].
As well as breast cancer, ADAM12 has also been found to be elevated in urine from
patients with bladder cancer, compared with healthy control subjects [56]. Indeed,
measurement of ADAM12 appeared to be a more sensitive diganostic marker for blad-
der cancer that standard cytology. Although levels were increased in patients with
early stage disease, including those with superficial non-invasive disease and superficial
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invasive disease, concentrations tended to be higher in those with the largest invasive
tumours. In the small number of cases studied, urinary ADAM12 levels decreased fol-
lowing surgical removal of the bladder cancer but increased again with recurrent dis-
ease [56]. This latter finding suggests that measurement of urinary ADAM12 may be
suitable for monitoring patients with bladder cancer.
One of the first ADAMs shown to be elevated in serum from patients with cancer
was ADAM28 [57]. Using ELISA, Kuroda et al [57] found that serum levels of this
ADAM in patients with non-small cell lung cancer were approximately 5-fold greater
than levels in a healthy control group. As with urinary levels of ADAM12 in breast
cancer, serum levels of ADAM28 increased progressively with increasing disease stage.
Interestingly, the diagnostic acuracy of ADAM28 appeared to be higher than that of
one of the establised marker for non-small cell lung cancer, i.e., carcinoembryonic anti-
gen (CEA).
ADAMs as prognostic markers
Prognostic markers are important in the management of patients with cancer as
they help avoid the overtreatment of indolent disease and undertreatment of
aggressive cases. Ideally, a new biological prognostic marker should provide addi-
tional or independent information to that available from the conventional factors
such as tumour size, tumour grade and metastasis to local lymph nodes. New
prognostic markers are most urgently needed for cancers such as breast and pros-
tate cancer. In breast cancer, prognostic markers may help identify those patients
whose prognosis is so good that they are unlikely to benefit from receiving adju-
vant chemotherapy. The corollory is that the same marker(s) can help identify
patients with aggressive disease that may derive benefit from receiving such ther-
apy. As certain ADAMs have been implicated in tumour development and pro-
gression, it is not surprising that they have been investigated for potential
prognostic impact in patients with cancer.
One of the best validated ADAMs for predicting patient outcome is ADAM17 in
breast cancer. Using ELISA, McGowan et al showed that patients with breast cancers
expressing high levels of ADAM17 protein had significantly shorter overall survival
compared to those with low expression of the protein [31]. Importantly, the prognostic
impact of ADAM17 was independent of tumour size, grade and lymph node status.
Although the ELISA used in this study detected both the precursor and active forms
of ADAM17, a previous study found that the active form was more associated with
breast cancer progression than the precursor form [16]. As well as ADAM17 protein,
high expression of ADAM17 mRNA was also found to predict adverse outcome in
patients with breast cancer [15].
Another ADAM associated with outcome in patients with breast cancer is ADAM15.
Four isoforms or variants of this ADAM have been described, ADAM15-A, ADAM15-
B, ADAM15-C and ADAM15-D. These different forms of ADAM15 have been shown
to have different effects in vitro [29]. Thus, ADAM15-A was found to increase cell
invasion, migration and adhesion, while ADAM15-B was shown to decrease adhesion.
Although these 2 variants had different effects on adhesion in vitro, high expression of
both predicted shortened relapse-free survival in lymph node-negative breast cancer
patients. ADAM15-C, on the other hand, correlated with improved relapse-free survi-
val in lymph node-positive but not in lymph node-negative patients.
Duffy et al. Clinical Proteomics 2011, 8:9
http://www.clinicalproteomicsjournal.com/content/8/1/9
Page 7 of 13
One of the cancers for which new prognostic markers are most urgently required is
prostate cancer. Although prostate cancer is the most common malignancy affecting
males, most of these tumours are indolent and never progress to a symptomatic stage.
However, a minority are aggressive and rapidly progress causing morbidity and mortal-
ity. A major everyday problem in the management of men with newly diagnosed
prostate cancer is therefore differentiating men with indolent disease from those with
life-threatening disease.
Using immunohistochemistry, Fritzche et al [28], showed that increased expression of
ADAM9 in prostate cancer was significantly associated with shortened relapse-free
survival as measured by increasing serum PSA levels. As with ADAM17 in breast
cancer, the prognostic impact of ADAM9 in prostate cancer was independent of the
conventionally used factors for this malignancy such as tumour size, Gleason grade
and preoperative PSA level. This independent prognostic impact of ADAM9 was found
in both the total population of patients investigated as well as in those treated with
anti-androgens [28]. Other malignancies for which ADAM9 has also been shown to
have prognostic value include renal [27] and pancreatic cancers [58].
ADAMs as therapy predictive markers
Predictive markers are factors that are associated with upfront response or resistance
to a particular therapy [59]. Predictive markers are important in the management of
cancer patients as tumours of the same histological type or tissue of origin vary widely
in their response to most available systemic therapies. Ideally, therefore, markers
should be available that predicts likely response. Markers that predict resistance how-
ever, may also be helpful. In this latter situation, if available, patients could receive an
alternative therapy that may be more beneficial. If an effective alternative therapy is
unavailable, these patients could volunteer to participate in clinical trials evaluating
new therapies or they could make an informed decision to avoid the needless costs
and toxicity of likely ineffective therapy [59].
In one of the few studies carried out to date on ADAMs as therapy predictive
biomarkers, Siewerts et al [60] reported that high levels of mRNA for ADAM9 and 11
but not for ADAM10 or ADAM12 were associated with increased benefit from tamox-
ifen in patients with recurrent breast cancer [60]. This finding was especially true for
patients whose primary tumour contained large amounts of stroma. ADAM9 but not
ADAM11 provided independent predictive information over estrogen receptors,
progesterone receptors, menopausal status and dominant site of relapse.
Summary and Conclusion on ADAMs as Cancer Biomarkers
Although the above studies indicating a cancer biomarker potential for different
ADAMs are promising, they all require confirmation in larger and prospective studies.
For evaluating a potential cancer diagnostic role for the ADAMs, it is important that
control samples are taken from subjects with a relevant benign disease rather from a
healthy population. For studies evaluating a prognostic impact, homogenously-mana-
ged groups of patients should be investigated. Such a study is best carried out prospec-
tively although a sufficiently high-powered retrospective analysis lacking bias should
also provide reliable results. Predictive biomarkers are most conveniently evaluated in
either the neoadjuvant or advanced disease settings, i.e., where measurable disease is
present. In the adjuvant setting, predictive markers should be investigated as part of a
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randomised trial in which the marker is used to determine response in the treatment
arm while a potential prognostic value can be evaluated in the control arm without
systemic treatment.
ADAMs as Therapeutic Targets for the Treatment of Cancer
Since considerable evidence from model systems suggest that specific ADAMs are
causally involved in cancer formation and progression, it might be expected that inhi-
bition of these proteases could be used to treat cancer. At least 4 potential approaches
exist to block ADAM protease activity. These include use of low molecular weight syn-
thetic inhibitors [see below], purified or synthetic forms of ADAM prodomains [61,62],
modified TIMPs [63,64] and monoclonal antibodies [65]. Of these potential
approaches, only the use of low molecular weight synthetic inhibitors has been
subjected to detailed investigation.
Most of the low molecular weight ADAM inhibitors use hydroxamate as the zinc
binding group and were designed to bind to the MMP-like catalytic site [66-69].
Although the majority of those described, inhibited a number of MMPs as well as
some ADAMs, a small number were relatively selective for specific ADAMs, especially
ADAM10 and/or ADAM17 [32-34,70-75] (Table 2). Of the compounds listed in
Table 2, the most widely investigated for anticancer activity are INCB3619 and
INCB7839 [Incyte Corporation, Wilmington, DE] [32-34,70-72].
INCB3619 is an orally-active low molecular weight molecule that selectively inhibits
ADAM10 and ADAM17 with low IC50 values [14 and 22 nmoles/L, respectively] [33].
It has been shown to inhibit tumour cell growth in several different preclinical models.
Thus, in an early study, with non small cell lung cancer [NSCLC] cells in culture,
INCB3619 was found to block release of the HER3 ligand, heregulin, rendering these
cells sensitive to the EGFR inhibitor, gefitinib [32]. Also, using NSCLC cell, INCB3619
increased apoptosis and reduced the apoptotic threshold for response to paclitaxel
[32]. Consistent with this finding, the inhibitor decreased tumour growth and
enhanced the therapeutic benefit of paclitaxel in a xenograft model of these cells.
As well as lung cancer, INCB3619 has also been shown to block the growth of breast
cancer. Thus, INCN3619 was shown to synergise with paclitaxel in inhibiting growth of
breast cancer in a xenograft model [32]. In a different study, although the addition of
this compound to MCF-7 breast cancer cells in vitro resulted in minimal growth inhi-
bition, when combined with the dual EGFR/HER2 tyrosine kinase inhibitor, GW2974
(Sigma Aldrich), synergistic growth inhibition was observed [33]. The combination of
INCB3619 and GW2974 also gave rise to decreased phosphorylation of ERK and AKT,
Table 2 Selective ADAM inhibitors
Inhibitor Target ADAM Company Refs
INCB3619 10, 17 Incyte, Wilmington, DE [32-34]
INCB7839 10,17 Incyte [34,70-72]
WAY-022 17 Wyeth-Aherst, Pearl River, NY [73]
GI254023X 10 Glaxo Smith Kline [74]
GW280264X 10,17 Glaxo Smith Kline [74]
TMI-2 17 Pfizer [75]
KB-R7785 12 Organon, Osaka, Japan [80]
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suggesting blockage of the MAPK pathway. Using a xenograft breast cancer model, an
inhibitor related to INCB3619, i.e., INCB7839 was found to decrease tumour volume [34].
However, when combined with the tyrosine kinase inhibitor, lapatinib, complete inhibition
of tumour growth was observed. An important finding with the animal models investi-
gated was that administration of INCB3619, in contrast to previous studies with MMP
inhibitors [76,77], did not appear to induce musculoskeletal side effects [33].
INCB7839 is currently undergoing early clinical trials in HER2-positive advanced
breast cancer patients [71,72]. Preliminary results suggest that this drug is generally
well tolerated with no significant adverse effects that might be expected from inhibi-
tion of MMPs (musculoskeletal side effects) or EGFR-related kinases (skin rash).
Furthermore, there was no evidence of drug-induced increases in liver enzymes, bone
marrow toxicity or increase in cardiomyopathy. In a recently reported abstract [72],
administration of INCB7839 and trastuzumab to 51 patients with advanced HER2-posi-
tive breast cancer induced response in 13/26 (50%) evaluable patients. In 14 patients
where the INCB7839 plasma concentration exceeded the IC50 for HER2 cleavage,
response was obtained in 9 (64%). Previous studies had shown that administration of
trastuzumab monotherapy to patients with advanced breast cancer induced response
rates of approximately 14-35% [78,79]. Thus, it would appear that the addition of
INCB7839 to trastuzumab increased efficacy. Phase III clinical trials however, will be
necessary to confirm this finding.
Potential side effects from anti-ADAM treatments
Most of our information on the potential side-effects of anti-ADAM inhibitors has
been derived from clinical trials involving the use of ADAM17 inhibitors to treat
patients with rheumatoid arthritis [68,69]. Unfortunately, most of these studies were
limited to phase I and phase II trials because of lack of efficacy and/or hepatotoxicity.
The origin of the hepatotoxicity is unclear. However, as mentioned above, early results
from phase I/II trials with the dual ADAM10/17 inhibitor INCB7839 do not suggest
major toxicity problems with this agent. As mentioned above, a particularly encoura-
ging finding with INCB3619 and INCB7839 is that they do not appear to cause muscu-
loskeletal side effects [33], which was a major problem with the early metalloproteinase
inhibitors investigated [76,77]. Continued caution however, with respect to toxicity, will
be necessary, especially as ADAM10 and ADAM17 act on wide variety of membrane
proteins [1,2].
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